Bain Capital, LP is one of the world’s leading private multi-asset alternative investment firms with over $105 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into several asset classes including private equity, credit, public equity, venture capital and real estate. We leverage our shared platform to capture cross-asset class opportunities in strategic areas of focus. With offices on four continents, our global team aligns our interests with those of our investors for lasting impact.

Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact [email protected].

Orly Mishan

Orly Mishan

Life Sciences


Orly Mishan joined Bain Capital Life Sciences in 2017. Prior to joining Bain Capital, she was the Vice President of Corporate Strategy & Development at Biogen. Before Biogen, Ms. Mishan spent a decade at Boston Scientific driving strategy, business development, restructuring and product development. Prior to this, Ms. Mishan led business and product development at a venture-funded diagnostics company, Senseonics. In 1997, she joined Pfizer where she was the commercial lead on product development for products in diabetes and Metabolic diseases and helped drive transactions across multiple therapeutic areas. Ms. Mishan began her career at McKinsey & Company in New York and Paris and focused on strategy and M&A for large pharma clients during her time at McKinsey in Boston.


Ms. Mishan received a BA in Economics and Political Science from Columbia College.